We identified two Mycobacterium tuberculosis tRNAfMet-inactivating toxins that can be exploited for antibiotic development
Excited to dip our toes into breast cancer research with this R21 grant with Co-Investigator Yuh-Hwa Wang to the University of Virginia School of Medicine
This RO1 grant supports research that studies how ribosome stalling in Mycobacterium tuberculosis can be used as a tool to better understand how this pathogen avoids being killed by our immune response and antibiotics
This R21 grant supports research that examines the molecular mechanisms that enable Mycobacterium tuberculosis to reprogram its physiology in response to stress
Nancy is the Principal Investigator on a five year team science RO1 grant with Drs. Robert Husson (Boston Children’s Hospital, Harvard Medical School) and Ming Ouyang (UMass-Boston) to study the role of MazF toxins in Mycobacterium tuberculosis stress survival and establishment of latent tuberculosis.
The Woychik lab was awarded a new NIH R21 grant to study emerging mycobacterial pathogens now common in the US.
The Woychik and Husson laboratories were awarded a new NIH grant beginning 12/1/2016. The grant supports research to study how the bacterium that causes tuberculosis in humans, Mycobacterium tuberculosis, has the unique ability to evade being killed by our immune system and is able to persist for long periods of time in its host as a latent infection.
The Woychik lab and their collaborators Dr. Robert Husson (Boston Children’s Hospital/Harvard Medical School) and Dr. Bryce Nickels (Waksman Institute/Rutgers University) were just awarded an NIH grant to study how changes in the transcriptome influence whether patients infected with Mycobacterium tuberculosis develop latent tuberculosis.